GSK to take over remaining stake in GSKNB
Following the transaction, which is still subject to approval of Peoples Republic of China’s authorities, GSK will become the sole owner of GSKNB. With this acquisition, GSK intends
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.